Turning Point Therapeutics, Inc.
TPTXDelisted Aug 17, 2022- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595893
Turning Point Therapeutics, Inc. was delisted on Aug 17, 2022; its insiders filed their last Form 4 on Aug 17, 2022; 209 institutions reported holding it in 13F filings for Q2 2022, worth $3.29B in total; Soros Fund Management was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:39 PM ET
Revenue flow, FY2021
Where the revenue went in FY2021, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2021: $236.6M (767.3% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Jan 18, 2022 | Jan 11, 2021 | Mar 16, 2020 |
| Revenue | $30.8M | $25.0M | – |
| Operating expenses | $268.8M | $186.8M | $77.7M |
| Research and development | $193.0M | $113.4M | $57.9M |
| Selling, general and administrative | $75.8M | $73.4M | $19.8M |
| Operating income | -$238.0M | -$161.8M | -$77.7M |
| Income tax | $0 | $0 | $0 |
| Net income | -$236.6M | -$157.3M | -$72.1M |
| Margins and growth | |||
| Operating margin | -772.0% | -647.3% | – |
| Net margin | -767.3% | -629.2% | – |
| Revenue growth, year over year | +23.3% | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Jan 18, 2022 | Jan 11, 2021 | Mar 16, 2020 |
| Cash and equivalents | $427.9M | $554.1M | $48.2M |
| Short-term investments | $553.7M | $568.4M | $361.0M |
| Total current assets | $992.5M | $1.13B | $414.9M |
| Property, plant and equipment | $3.82M | $2.60M | $2.69M |
| Total assets | $1.00B | $1.14B | $422.2M |
| Accounts payable | $5.66M | $5.22M | $2.15M |
| Total current liabilities | $47.1M | $24.4M | $14.0M |
| Shareholders' equity | $954.4M | $1.11B | $404.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2021 | FY2020 | FY2019 |
|---|---|---|---|
| Period end | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
| Filing | 10-K | 10-K | 10-K |
| Reported | Jan 18, 2022 | Jan 11, 2021 | Mar 16, 2020 |
| Operating cash flow | -$153.9M | -$82.8M | -$57.8M |
| Capital expenditures | $2.43M | $1.26M | $1.74M |
| Free cash flow | -$156.3M | -$84.1M | -$59.5M |
| Stock-based compensation | $58.6M | $64.2M | $12.7M |
| Investing cash flow | $5.46M | -$210.0M | -$361.1M |
| Financing cash flow | $24.0M | $798.7M | $366.0M |
| Net change in cash | -$124.4M | $505.9M | -$52.8M |
| Ratio | |||
| Stock-based compensation, % of revenue | 189.9% | 256.7% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 1, 2022 | 50.1M | +1.3% | SEC |
| May 3, 2022 | 49.7M | +1.0% | SEC |
| Feb 22, 2022 | 49.6M | +1.3% | SEC |
| Nov 2, 2021 | 49.5M | +2.7% | SEC |
| Aug 2, 2021 | 49.4M | +17.2% | SEC |
| Apr 30, 2021 | 49.2M | +36.8% | SEC |
| Feb 23, 2021 | 49.0M | +36.3% | SEC |
| Nov 6, 2020 | 48.2M | +34.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.